Ozempic works by mimicking a natural gut hormone called GLP-1 that your body releases after eating. The active ingredient, semaglutide, activates GLP-1 receptors throughout your body to lower blood sugar, slow digestion, and reduce appetite. It’s a once-weekly injection approved for type 2 diabetes, though it’s widely known for causing significant weight loss as a side effect.
How It Lowers Blood Sugar
After you eat, your blood sugar rises, and your body normally responds by releasing insulin from the pancreas. Ozempic amplifies this response. When it activates GLP-1 receptors on pancreatic cells, your pancreas releases more insulin, but only when blood sugar is actually elevated. This glucose-dependent mechanism is a key safety feature: the drug doesn’t push insulin release when your blood sugar is already normal, which lowers the risk of dangerous blood sugar drops.
At the same time, Ozempic suppresses glucagon, a hormone that tells your liver to dump stored sugar into your bloodstream. By dialing down glucagon while dialing up insulin, the drug attacks high blood sugar from two directions. In clinical trials across the SUSTAIN program, participants taking the standard 1.0 mg dose saw their HbA1c (a measure of average blood sugar over three months) drop by roughly 0.4 to 1.1 percentage points more than those on comparison treatments. That’s a clinically meaningful change for most people with type 2 diabetes.
Why It Reduces Appetite
The appetite suppression people experience on Ozempic isn’t just willpower or a side effect of nausea. The drug directly acts on the brain. GLP-1 receptors sit in several brain regions that control hunger, fullness, and food reward, including the hypothalamus and brainstem. When semaglutide reaches these receptors, it triggers a cascade of signals that make you feel full sooner and less interested in food between meals.
Animal research has revealed how specific this process is. Neurons in a part of the hypothalamus called the DMH respond to GLP-1 drugs by triggering immediate meal termination, essentially flipping a switch that says “stop eating.” These same neurons become active before food even arrives, during the anticipation phase, suggesting they help regulate how much you plan to eat before you take a bite. Other neurons in a region called the ARC work differently: Ozempic activates cells that suppress appetite while quieting cells that drive hunger. It’s a coordinated effort across multiple brain circuits.
There’s also a reward component. GLP-1 receptors exist in the brain’s dopamine pathways, the same circuits involved in pleasure and motivation. Research shows that GLP-1 drugs can dampen the dopamine response to rewarding stimuli, which may explain why some people on Ozempic report reduced cravings not just for food but for alcohol and other substances.
How It Slows Digestion
Ozempic significantly slows the rate at which food leaves your stomach, a process called gastric emptying. In people not taking the drug, the stomach typically empties about half its contents in roughly 95 minutes. On GLP-1 drugs like semaglutide, that time stretches to about 138 minutes on average, a delay of around 36 minutes.
But averages don’t tell the full story. One study measuring stomach contents four hours after a meal found that before semaglutide treatment, only about 7% of food remained in the stomach. After 13 weeks on the drug, 37% of the meal was still sitting there at the four-hour mark. For people with a BMI of 30 or higher, the delay tends to be even more pronounced. This slower emptying contributes to feeling full longer after eating, but it’s also the main reason many people experience nausea, bloating, and other digestive discomfort, especially early in treatment.
Weight Loss on Ozempic
Although Ozempic is FDA-approved only for type 2 diabetes, weight loss is a well-documented effect of the drug. The combination of reduced appetite, slower digestion, and changes in food reward signals leads most people to simply eat less without consciously dieting. However, Ozempic maxes out at a 2.0 mg weekly dose, while Wegovy (the same molecule, semaglutide, branded specifically for weight management) goes up to 2.4 mg as an injection. That higher ceiling is one reason Wegovy tends to produce greater weight loss in clinical trials and is the only semaglutide product FDA-approved for that purpose.
People with type 2 diabetes generally lose less weight on semaglutide than people without diabetes. This likely reflects the metabolic complexity of diabetes itself rather than a limitation of the drug’s mechanism.
Cardiovascular Protection
Beyond blood sugar and weight, Ozempic reduces the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, by about 18% in people with type 2 diabetes. This benefit appears to come from multiple pathways: lower blood sugar, weight loss, reduced inflammation, and possibly direct effects on blood vessels. For people with type 2 diabetes who already have heart disease or are at high risk for it, this cardiovascular protection is often a major reason doctors choose semaglutide over other diabetes medications.
How the Dosing Works
Ozempic is injected once a week under the skin of the abdomen, thigh, or upper arm. The starting dose of 0.25 mg is purely a ramp-up phase designed to let your body adjust and minimize nausea. It doesn’t meaningfully lower blood sugar. After four weeks, the dose increases to 0.5 mg. If blood sugar control still isn’t adequate after at least another four weeks, your doctor may raise it to 1.0 mg, which is the maximum recommended dose listed in the original FDA labeling (though a 2.0 mg dose is now also available).
This gradual titration matters. The digestive side effects, particularly nausea, vomiting, and diarrhea, are most common during dose increases. Starting low and climbing slowly gives your gut time to adapt.
Safety Considerations
Ozempic carries a boxed warning (the FDA’s most serious label warning) about a potential risk of thyroid C-cell tumors. In rodent studies, semaglutide caused a dose-dependent increase in these tumors, including both benign and cancerous forms like medullary thyroid carcinoma. Whether the same risk applies to humans remains unknown, but the drug is not recommended for anyone with a personal or family history of medullary thyroid carcinoma or a rare condition called Multiple Endocrine Neoplasia syndrome type 2.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. These tend to be worst during the first few weeks at each new dose and improve over time for most people. Pancreatitis is a rare but serious risk, and gallbladder problems have also been reported at higher rates in people taking GLP-1 drugs.